Critical parameters in targeted drug development: the pharmacological audit trail
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference115 articles.
1. Inhibition of mutated, activated BRAF in metastatic melanoma;Flaherty;N Engl J Med.,2010
2. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med.,2007
3. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med.,2002
4. Can the pharmaceutical industry reduce attrition rates?;Kola;Nat Rev Drug Discov.,2004
5. High drug attrition rates—where are we going wrong?;Hutchinson;Nat Rev Clin Oncol.,2011
Cited by 62 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. MXenes as the theranostic materials;MXenes as Surface-Active Advanced Materials;2024
2. Optimizing the FDA’s Project Optimus: opportunities and challenges;Nature Reviews Clinical Oncology;2023-12-21
3. Realizing the Promise of Project Optimus: Challenges and Emerging Opportunities for Dose Optimization in Oncology Drug Development;CPT: Pharmacometrics & Systems Pharmacology;2023-11-15
4. HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies;Journal of Medicinal Chemistry;2023-04-05
5. The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations;Molecular Cancer Therapeutics;2023-03-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3